All In Biotech

Investigational drug · Phase 2

VH4011499

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV Infections.

Phase 2

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

8

Any phase or sponsor naming "VH4011499"

First trial start

2026

Oct 19, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VH4011499", any sponsor or status.

Conditions studied

As listed on its trial records.

  • HIV Infections

Approved drugs for the same conditions: Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "VH4011499" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for HIV Infections

  • rHuPH20Phase 35 trials

    Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma

  • TeropavimabTAB, GS-5423Phase 33 trials

    Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection

  • ZinlirvimabGS-2872, ZABPhase 33 trials

    Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection

  • 2 NRTIsPhase 32 trials

    Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections

  • ABC3TC STR, 3TC immediate releasePhase 32 trials

    GSK · HIV Infections

  • ARTPhase 32 trials

    GSK · HIV Infections, HIV-1 Infection

  • DTGPhase 32 trials

    Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections

  • BMS-663068Phase 31 trial

    GSK · HIV Infections

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.